Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Pfizer Inc. (NYSE:PFE) today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA.

"Polocard is a top OTC brand in Poland, and its acquisition will enhance our Consumer Healthcare portfolio and overall position in this key market," said Paul Sturman, President, Pfizer Consumer Healthcare. "We continue to focus on strategic opportunities that will expand our portfolio of leading brands, develop capabilities in high-growth categories and extend our global reach."

The acquisition of Polocard marks the latest of several investments by Pfizer in its Consumer Healthcare business over the last twenty-four months. Other notable transactions include the exclusive global license agreement with AstraZeneca for the OTC rights for NEXIUM (esomeprazole magnesium) and the acquisitions of Alacer, maker and distributor of Emergen-C products, now the largest selling branded Vitamin C line in the United States, and Ferrosan's Consumer Healthcare business, which broadened the unit's industry-leading dietary supplements portfolio as well as its geographic footprint in the Nordics, Russia and Central and Eastern Europe.

The financial terms of the Polocard deal were not disclosed.


Pfizer Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Serious heart attacks more likely to happen on a Monday